UniQure Introduces Breakthrough Gene Therapy AMT-130 for the Treatment of Huntington’s Disease
uniQure has introduced AMT-130 as the first and only investigational gene therapy to receive FDA Breakthrough Therapy designation for the treatment of Huntington’s disease.
AMT-130 works by delivering a microRNA that silences the mutant huntingtin gene responsible for the disease. This one-time treatment aims to slow the progression of the disease, offering hope to patients affected by the debilitating condition.
There are currently no approved therapies that can slow or modify the progression of the disease.
The FDA’s Breakthrough Therapy designation underscores the therapy’s potential to address a significant unmet need in the field. AMT-130 previously received Orphan Drug and Fast Track designations, adding to its growing profile as a revolutionary approach to Huntington’s disease.
Huntington’s disease is marked by progressive motor, cognitive, and psychiatric symptoms, severely impacting quality of life. With no approved therapies available to alter the disease’s course, AMT-130 has attracted significant attention. The therapy has shown promising interim results in Phase I/II clinical trials, with early data suggesting a slowing of disease progression over 24 months.
AMT-130 is the first and only investigational gene therapy to receive U.S. FDA Breakthrough Therapy designation for the treatment of Huntington’s disease.
